RAPT News
Archived Headlines
- US IPO Week Ahead: IPO market is ghosted with just 3 deals this week 10/25/19
- Cancer biotech RAPT Therapeutics revives IPO with an updated filing 10/22/19
- US IPO Weekly Recap: Sushi and SaaS succeed in a 4-IPO week 08/02/19
- RAPT Therapeutics postpones $75 million IPO 08/01/19
- US IPO Week Ahead: A 6-IPO week led by cannabis and the cloud 07/26/19
See more
US IPO Week Ahead: The IPO market takes its Thanksgiving break
One holdover and one SPAC plan to raise $235 million in the holiday week ahead. Nano-cap auto e-tailer LMP Automotive Holdings (LMPX) plans to raise $12 million at a $45 million market cap. After decreasing its proposed share offering and...read more
US IPO Weekly Recap: More deals price down in a 3-IPO week
Two biotechs and a Chinese real estate company entered the public market, accompanied by two SPACs. All three companies priced at the bottom of the range, while both SPACs upsized their unit offerings. Seven Chinese companies filed for US IPOs, along with two...read more
Immunology biotech RAPT Therapeutics prices IPO at $12 low end
RAPT Therapeutics, a Phase 1 biotech developing therapies for cancer and inflammatory diseases, raised $36 million by offering 3.0 million shares at $12, the low end of the range of $12 to $14. Insiders had indicated on purchasing $30 million of the deal. At IPO...read more
Cancer biotech RAPT Therapeutics re-launches downsized $39 million IPO
RAPT Therapeutics, a Phase 1 biotech developing therapies for cancer and inflammatory diseases, announced new IPO terms with a lower proposed deal size on Monday after postponing on August 1, 2019. The South San Francisco, CA-based company now plans to...read more